IQVIA Holdings Inc.
IQV Healthcare Diagnostics & Research
IQVIA Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $16.3 billion, up 5.87% from fiscal 2024. In the quarter to June 2026, revenue grew 8.74%, EPS was flat, free cash flow grew 23.3% and total debt rose 3.29%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for ten consecutive years.
Follow IQV
IQVIA Holdings Inc. (IQV) P/S ratio
As of 16 October 2026, IQVIA Holdings Inc. (IQV) trades at a P/S ratio of 2.6×. Over the past ten years it has ranged from 1.2× (February 2016) to 4.0× (December 2021); the current reading is higher than 62% of that period. That is below the Diagnostics & Research industry median of 4.4× and below the Healthcare sector median of 3.4×.
P/S ratio, daily
Embed this chart
Annual newest first
| Period | P/S ratio | Change |
|---|---|---|
| FY2025 | 2.4× | 2.72% |
| FY2024 | 2.3× | (18.17%) |
| FY2023 | 2.8× | 6.48% |
| FY2022 | 2.7× | (31.81%) |
| FY2021 | 3.9× | 28.99% |
| FY2020 | 3.0× | 10.99% |
| FY2019 | 2.7× | 19.62% |
| FY2018 | 2.3× | 1.48% |
| FY2017 | 2.2× | 33.06% |
| FY2016 | 1.7× | 14.33% |
Quarterly newest first
| Period | P/S ratio | Change |
|---|---|---|
| Jun 2026 | 1.9× | 9.45% |
| Mar 2026 | 1.7× | (27.32%) |
| Dec 2025 | 2.4× | 16.87% |
| Sep 2025 | 2.0× | 17.87% |
| 42 more quarters | Free account |
Against its own ten years
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| LH Labcorp Holdings Inc. compare | 1.8× |
| DGX Quest Diagnostics Incorporated compare | 2.3× |
| IQV IQVIA Holdings Inc. | 2.6× |
| A Agilent Technologies, Inc. compare | 6.6× |
| MTD Mettler-Toledo International, Inc. compare | 7.9× |
| ILMN Illumina, Inc. compare | 8.8× |
| WAT Waters Corporation compare | 9.2× |
| IDXX IDEXX Laboratories, Inc. compare | 9.7× |
| NTRA Natera, Inc. compare | 20.7× |
| Diagnostics & Research industry median | 4.4× |
| Healthcare sector median | 3.4× |
| Market median | 1.9× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on IQV
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement